Market Experts Boost Positions Ahead of Axsome's Key FDA Review

Analysts raise approval odds to 85% for Auvelity's expansion into Alzheimer's agitation, as strong prescription growth fuels Axsome's 65% revenue surge.

A pivotal regulatory milestone is approaching for Axsome Therapeutics, drawing increased attention from investment analysts. The focus is on the potential expansion of the company's drug Auvelity (AXS-05) into a new treatment area, a decision that could significantly impact the firm's growth trajectory.

Analyst Confidence Rises on Regulatory Outlook

Market researchers are adjusting their models in anticipation of the U.S. Food and Drug Administration's upcoming verdict. The agency has set a target action date of April 30, 2026, for Auvelity's supplemental New Drug Application concerning the treatment of agitation associated with Alzheimer's disease. In a notable move, analysts at Guggenheim have increased their internal probability assessment for a favorable outcome from 75% to 85%, signaling growing confidence in the application's success.

Prescription Momentum Underpins Financial Performance

The optimistic sentiment is supported by robust commercial uptake data. According to figures from IQVIA, total prescriptions for Auvelity reached 16,777 in its 179th week on the market. The company's newer offering, Sunosi (Symbravo), is also gaining traction, recording nearly 1,300 prescriptions in its 41st week. This commercial execution is translating directly to the company's financial statements.

Axsome reported a 65% year-over-year increase in revenue for the fourth quarter of 2025, demonstrating a solid and expanding financial foundation. The combination of strong prescription growth and a promising regulatory pathway is creating considerable activity around the company's shares as investors position themselves ahead of the FDA's decision next year.